A phase I study to determine the dose of the combination of Yondelis [trabectedin] and doxorubicin for which neutropenia is manageable with the support of a granulocyte-colony stimulation factor in subjects with recurrent or persistent soft tissue sarcoma
Phase of Trial: Phase I
Latest Information Update: 09 Jan 2013
At a glance
- Drugs Doxorubicin (Primary) ; Trabectedin (Primary)
- Indications Soft tissue sarcoma
- Focus Adverse reactions
- 05 May 2011 Planned number of patients changed to 41.
- 06 Sep 2005 New trial record.